GlobeNewswire

Centrient Pharmaceuticals Initiates Patent Litigation in India Against Dalas Biotech Limited

Share

Centrient Pharmaceuticals (“Centrient”), the global leader in the production and commercialisation of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed a lawsuit against Dalas Biotech Limited (“Dalas”) for patent infringement.

ROTTERDAM, Holland, May 01, 2019 (GLOBE NEWSWIRE) -- Centrient Pharmaceuticals announced that on April 25, 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 247301. This patent, which is owned by Centrient, describes an enzymatic process for preparing amoxicillin trihydrate having a low free water content. By its complaint, Centrient seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use,  sale in India and exportation out of India of Dalas’ active pharmaceutical ingredient containing amoxicillin trihydrate produced by a process that amounts to infringement of Indian Patent No. 247301.

Karl Rotthier, CEO at Centrient said: “After having previously filed patent litigation against Sinopharm Weiqida Pharmaceuticals for patent infringement in India, and the Court granting an injunction since April 2017, Centrient shows that it will continue to rigorously enforce its IP assets worldwide against any additional potential infringers in India or abroad.”

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals. We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. 

With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our 2700 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. 

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm. 

Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPress release

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-621920.8.2019 09:00:00 CESTPressemelding

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis. Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions. In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study w

Nexstim reports good initial results on the use of Smartfocus® technology in treatment of major depressive disorder20.8.2019 09:00:00 CESTPress release

Press Release, Helsinki, 20 August 2019 at 10.00 am (EET) Nexstim reports good initial results on the use of Smartfocus ® technology in treatment of major depressive disorder Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD) – announces that the first white paper about the initial experiences of its NBT® system with SmartFocus® technology in treatment of MDD has been published. The white paper is published by Island Psychiatry PC, a New York -based TMS therapy provider and Nexstim. It reports the experiences in the first 10 consecutive patients completing treatment of MDD with Nexstim NBT® system at Island Psychiatry’s clinic. The treatment outcomes of these 10 adult patients were good. 50 % of the patients were in remission at the end of the treatment while 70 % had obtained a clinical response rate. These patient-reported outcomes are hi

SERSTECH AB: Half-year report 1 January – 30 June 201920.8.2019 08:45:00 CESTPress release

SALES INCREASE BY 200% FROM HIGHER MARKET ACCEPTANCE Second quarter 2019 Period 1 January - 30 June 2019 • Net sales: KSEK 5 089 (1 558, +227%) • Net sales: KSEK 8 340 (2 768, +201%) • Profit for the period: KSEK -3 349 (-2 166) • Profit for the period KSEK -7 008 (-5 599) • Earnings per share SEK -0,05 (-0,03) • Earnings per share: SEK -0,11 (-0,09) During Q2, we passed another set of important milestones on our way to becoming a significant player in the security industry and a more mature, professional organization. Our net sales numbers continued to move in the right direction, +227% compared to Q2 2018, and we received significant orders, expanded the reach of our sales network and signed another OEM agreement. We dramatically expanded our R&D capabilities and added dedicated roles for product management and quality assurance, both of which are imperative as our volumes continue to increase. Our operative cash flow continues to improve and for the first half of the year our operat

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso20.8.2019 08:00:00 CESTPress release

Metso Corporation, Stock exchange release on August 20, 2019, at 9:00 a.m. EEST Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the holding of mutual funds managed by BlackRock, Inc. of the total amount of shares and financial instruments entitling to shares of Metso. On August 16, 2019, BlackRock Inc.'s direct holding in Metso shares and in financial instruments entitling to shares fell below the 5 percent threshold. On August 14, 2019, BlackRock, Inc.'s total position in Metso amounted to less than 5 percent of Metso’s shares and votes. Metso’s total number of shares and votes is 150,348,256. BlackRock, Inc.’s holdings according to the notification: % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A + B) Res

Intention to list & Company Description20.8.2019 08:00:00 CESTPress release

GG St. Kongensgade 100 og 106 P/S Nasdaq First North, Copenhagen, Bond Market Ticker: GGSTK; ISIN: DK0030444401 For release: 20 August 2019 Intention to list the company’s floating rate (7%) secured bond loan 2019/2020 and company description The Director of GG St. Kongensgade 100 og 106 P/S announces that the Company intends to list its floating rate 7% secured bond loan 2019/2020 for trading on Nasdaq First North, Copenhagen. In connection with this, the Company has prepared a Company Description which has been approved by Nasdaq Copenhagen A/S. A copy of the Company Description accompanies this release and it may also be downloaded from the Investor Relations section of the Company’s website at www.gefiongroup.com The Company anticipates the first day of trading in its Bonds being 23 August 2019. GG St. Kongensgade 100 og 106 P/S, incorporated under the laws of Denmark with business registration number 38 30 68 47, having its registered office at c/o Gefion Group A/S, Østergade 1, 2